What question did this study set out to answer?

To compare outcomes of sequential afatinib-to-osimertinib therapy versus afatinib and chemotherapy in EGFR-mutant NSCLC.

March 23, 2026Open Access

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study

Key Points

To compare outcomes of sequential afatinib-to-osimertinib therapy versus afatinib and chemotherapy in EGFR-mutant NSCLC.
Conducted a multicenter study in Taiwan.
Compared two treatment regimens: sequential afatinib-to-osimertinib and afatinib with chemotherapy.
Analyzed overall survival rates in real-world settings.
Sequential afatinib-to-osimertinib therapy achieved an overall survival exceeding 55 months.
Outcomes were competitive with contemporary combination treatments.

Abstract

Sequential afatinib-to-osimertinib therapy achieved remarkable OS exceeding 55 months in real-world practice, with outcomes appearing competitive with contemporary combination strategies. These findings support sequential TKI therapy as a durable and effective alternative that warrants prospective validation.

AI से पूछें

Bookmark

View Full Paper